Hilltop Wealth Advisors LLC Makes New $842,000 Investment in Johnson & Johnson (NYSE:JNJ)

Hilltop Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,077 shares of the company's stock, valued at approximately $842,000. Johnson & Johnson comprises about 0.5% of Hilltop Wealth Advisors LLC's holdings, making the stock its 26th largest holding.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Vanguard Group Inc. raised its position in Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after purchasing an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC grew its holdings in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after purchasing an additional 1,561,036 shares during the period. Northern Trust Corp increased its holdings in shares of Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter valued at about $4,390,037,000. Finally, Wellington Management Group LLP raised its holdings in shares of Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock valued at $3,522,447,000 after purchasing an additional 431,205 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Morgan Stanley lifted their price target on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Finally, Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Price Performance

NYSE JNJ traded up $0.24 during trading hours on Friday, reaching $156.90. 6,587,488 shares of the company's stock were exchanged, compared to its average volume of 7,947,702. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a market cap of $377.52 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a fifty day moving average of $153.84 and a 200-day moving average of $153.72.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.31%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.